Concepedia

Marisol Herrera Marmolejo

MH

3

Publications

522

Citations

3

H-Index

2012

Active since

Affiliations

Bristol-Myers Squibb (Germany)(Current)

Marisol Herrera Marmolejo is an author at Bristol-Myers Squibb (Germany) specializing in pharmacotherapy, medicine, and pharmacology.

Top concepts

MedicinePharmacologyPharmacotherapyObesityDiabetesNephrologyHypertensionRenal DiseaseMetabolic SyndromeCardiovascular Disease

Publications per year

2012–2023

3

Publications

3

Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial

Robert R. Henry, Alexander V. Murray, Marisol Herrera Marmolejo et al. · International Journal of Clinical Practice · 2012 · 309 citations

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

Katherine R. Tuttle, Sibylle J. Hauske, María Eugênia Fernandes Canziani et al. · The Lancet · 2023 · 151 citations · Full text

Hypertension, Renal Function, Renal Disease +10

Efficacy and safety of triple therapy with dapagliflozin add‐on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes

Chantal Mathieu, Marisol Herrera Marmolejo, José Gerardo González‐González et al. · Diabetes Obesity and Metabolism · 2016 · 62 citations

Obesity, Metabolic Syndrome, Diabetes Management +13

Rows per page

1–3 of 3